https://www.overlandtx.com/publication/development-of-a-novel-allogeneic-%ce%b3%ce%b4-t-platform-for-off-the-shelf-adoptive-cell-therapy-for-oncology-and-autoimmune-diseases/2024-07-30T18:08:21+08:00https://www.overlandtx.com/publication/g-protein-coupled-receptor-class-c-group-5-member-d-gprc5d-and-b-cell-maturation-antigen-bcma-bi-specific-dual-chimeric-antigen-receptors-cars-effectively-address-antigen-escape-and-tumor-hetero/2024-07-30T18:15:11+08:00https://www.overlandtx.com/publication/a-gprc5d-and-bcma-bispecific-car-t-product-demonstrated-dual-antigen-targeting-capability-and-efficacy-against-multiple-myeloma-cells-bearing-bcma-mutations-associated-with-treatment-resistance/2024-11-26T19:01:52+08:00